Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of OP-2100 in relapsed or refractory high-risk myelodysplastic syndrome or high-risk chronic myelomonocytic leukemia
jRCT2071220035Phase 1Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Aug 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OR-2100 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Incidence rate of dose-limiting toxicity in Cycle 1. Started Aug 2022; status: completed.
02
Drugs
OR-2100
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on jRCT2071220035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220035.